Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 September 2023
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Drug-eluting stents for the treatment of coronary artery disease (TA152)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 18 November 2020Published: 23 July 2008
Guidance on the use of coronary artery stents (TA71)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 18 November 2020Published: 22 October 2003
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 October 2019
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2016
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) (TA351)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2015
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2014
Ticagrelor for the treatment of acute coronary syndromes (TA236)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2011
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 July 2011Published: 26 November 2003
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2010
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 March 2010Published: 5 September 2002
Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 October 2002
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC